Imaging of Coronary Plaques in Participants Treated With Evolocumab
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.
Also called NCT03570697
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 164 participants
- Sponsor
- Registry
-
NCT03570697 -
2017-003236-37
-
- Other papers using this trial's data
- Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Czechia, Germany, Hungary, Italy, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT03570697. Randomized; triple masking; primary purpose treatment. Start 2018-11-19 (actual); primary completion 2020-12-18 (actual). Results posted on 2021-11-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Imaging of Coronary Plaques in Participants Treated With Evolocumab
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Statin therapy
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct03570697- Content hash
2bae01a4a69934e433a77367fd30d8471da99394f182a1a81cd5b39d04fc2f12